china market

Hi Guys,

Last minute today IBA had a very good announcement and that is the entry into the China market.Looks like IBA is making waves as the merger with isoft coming to fruitation and this bang.IBA would become the world leader in ehealth.Read on

ANNOUNCEMENT TO THE ASX
IBA solutions selected for new hospital in Shanghai
Sydney – 30, April, 2007 – IBA Health Limited (ASX:IBA) Australia’s largest ASX listed eHealth company
announced today that IBA’s Chinese subsidiary, Jian Zhong (People’s Health) has been selected as
preferred vendor to supply administrative, doctors desktop and telehealth systems to Yuyan hospital in the
Huangpu District of Shanghai.
Yuyan hospital is a 100 bed, category 1A Hospital co-located with a 300 bed “older persons” home spread
over 12 floors and is located in the most densely populated district in the world, the Huanhpu District.
Yuyan will implement IBA’s administrative patient management system, using smart card technology to
communicate on-line to Yiaboa (Shanghai’s Public Health Insurance Funder) for point of care claiming and
integration with the doctors desktop. Yuyan will also implement modules from People’s Health Solution that
supports patient and doctor call centre capability and video and voice collaboration with health professionals
across the internet.
IBA’s People’s Health’s General Manager Mr Anthony Liu said “our business plan forecasts a significant
market for functionality that includes patient and health professional collaboration along side of
administrative systems; we are pleased that in such a short time we have been able to secure our first
combined product sale. We now have e-health implementations in two of the 18 districts of Shanghai with
discussions in other provinces and our 180 plus hospital clients proving positive. Project planning with Yuyan
Hospital will commence in May, with implementation commencing in July and completion expected in
October this year.” concluded Mr Liu.
The Yuyan opportunity builds on the Changning e-health project which when fully implemented will connect
11 hospitals providing health professionals and patients with the ability to share patient data.
The Yuyan and the Changning projects both provide a large scale solution that can be offered IPTV based
health care services. This capability is being developed by People’s Health in parallel to the roll out of the ehealth
systems.
End of release
For further information contact:
Steve Garrington
CEO
IBA Health Limited
Phone: +61 2 8251 6700
Email: [email protected]
Media Contacts:
Greg King
Communications and Business Development Director
IBA Health Ltd
Phone +61 413 62 11 11
Email: [email protected]
About IBA Health
IBA Health Limited (ASX-IBA) is the largest health information technology company listed on the Australian Securities Exchange.
IBA Health provides information and communication solutions to connect providers, payers, patients and communities. IBA Health’s
range of systems are designed to support workflows across all health sectors including hospitals, clinics, aged and community care
facilities, primary care as well as claims and payments processes.
IBA Health has a global team of over 500 health and technology professionals who work with healthcare providers to bring an in-depth
of experience to address all aspects of their partners' care delivery needs.
IBA Health has over 500 hospital and clinic installations covering Australia, New Zealand, South East Asia, China, India, The Middle
East and South Africa. Industry leading customers include tertiary research and teaching facilities and multi enterprise care delivery
organisations.
In Australia IBA Health is a leading provider to over 5,000 Primary Care providers, 300 Aged and Community Care facilities, 50% of
Private Hospitals, public hospitals and the Australian Defence Force. With one of the largest eHealth Network in the Southern
Hemisphere IBA is at the forefront of transmitting both financial and clinical data to General, Specialist and Allied Health professionals,
Medicare Australia and Private Health Funds.
For more information on IBA Health, please visit the Company’s website at www.ibahealth.com.
Notice Of Dealing Disclosure Requirements Under The UK City Code on Takeovers and Mergers
Under the provisions of Rule 8.3 of the Takeover Code (the “Code”), if any person is, or becomes, “interested” (directly or indirectly) in
1% or more of any class of “relevant securities” of IBA Health Limited or of iSOFT Group plc, all “dealings” in any “relevant securities” of
that company (including by means of an option in respect of, or a derivative referenced to, any such “relevant securities”) must be
publicly disclosed by no later than 3.30 pm (London time) on the London business day following the date of the relevant transaction.
This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is
otherwise withdrawn or on which the “offer period” otherwise ends. If two or more persons act together pursuant to an agreement or
understanding, whether formal or informal, to acquire an “interest” in “relevant securities” of IBA Health Limited or iSOFT Group plc, they
will be deemed to be a single person for the purpose of Rule 8.3.
Under the provisions of Rule 8.1 of the Code, all “dealings” in “relevant securities” of IBA Health Limited, or of iSOFT Group plc by IBA
Health Limited or iSOFT Group plc, or by any of their respective “associates”, must be disclosed by no later than 12.00 noon (London
time) on the London business day following the date of the relevant transaction.
A disclosure table, giving details of the companies in whose “relevant securities” “dealings” should be disclosed, and the number of such
securities in issue, can be found on the Takeover Panel’s website at www.thetakeoverpanel.org.uk.
“Interests in securities” arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in
the price of securities. In particular, a person will be treated as having an “interest” by virtue of the ownership or control of securities, or
by virtue of any option in respect of, or derivative referenced to, securities.
Terms in quotation marks are defined in the Code, which can also be found on the Panel’s website. If you are in any doubt as to
whether or not you are required to disclose a “dealing” under Rule 8, you should consult the Panel.